Spyre Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-27.4%projected annual EPS growth
Analyst Coverage
14analysts covering
FY EPS (est.)
-$2.83next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q4 2026 SPY072 PsA and axSpA Sub-studies Readout | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
SPY001 Robarts Histopathology Index (RHI) Reduction Quarterly9.2Target: Statistically significant reduction from baseline
SPY002 Robarts Histopathology Index (RHI) Reduction Quarterly10.7Target: Statistically significant reduction from baseline
Pro Forma Cash Balance Quarterly1.2BTarget: Sufficient capital to fund operations into 2H 2029
Watch Items
- SPY003 (anti-IL-23) Part A Induction Topline DataTrigger: Q3 2026 ReadoutAction: Evaluate clinical efficacy and safety profile to complete proof-of-concept for the monotherapy components.
- SKYWAY Phase 2 Basket Trial Readouts (SPY072 in Rheumatic Diseases)Trigger: Q3 2026 (RA) and Q4 2026 (PsA, axSpA) ReadoutsAction: Assess proof-of-concept data across rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.
- SKYLINE Part B Combination Cohorts EnrollmentTrigger: Initiation of Part B global enrollmentAction: Monitor enrollment progress of pairwise combination arms (SPY120, SPY130, SPY230) to deliver combination proof-of-concept data in 2027.
Research as of 20 Jun 2026